Nitric oxide (NO) is a key physiological mediator and disturbed regulation of NO release is associated with the pathophysiology of almost all inflammatory diseases. A multitude of inhibitors of NOSs (nitric oxide synthases) have been developed, initially with low or even no selectivity against the constitutively expressed NOS isoforms, eNOS (endothelial NOS) and nNOS (neuronal NOS). In the meanwhile these efforts yielded potent and highly selective iNOS (inducible NOS) inhibitors. Moreover, iNOS inhibitors have been shown to exert beneficial anti-inflammatory effects in a wide variety of acute and chronic animal models of inflammation. In the present mini-review, we summarize some of our current knowledge of inhibitors of the iNOS isoenzyme, their biochemical properties and efficacy in animal models of pulmonary diseases and in human disease itself. Moreover, the potential benefit of iNOS inhibition in animal models of COPD (chronic obstructive pulmonary disease), such as cigarette smoke-induced pulmonary inflammation, has not been explicitly studied so far. In this context, we demonstrated recently that both a semi-selective iNOS inhibitor {L-NIL [N6-(1-iminoethyl)-L-lysine hydrochloride]} and highly selective iNOS inhibitors (GW274150 and BYK402750) potently diminished inflammation in a cigarette smoke mouse model mimicking certain aspects of human COPD. Therefore, despite the disappointing results from recent asthma trials, iNOS inhibition could still be of therapeutic utility in COPD, a concept which needs to be challenged and validated in human disease.
Skip Nav Destination
Article navigation
August 2009
-
Cover Image
Cover Image
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
Conference Article|
July 22 2009
Inhibition of inducible nitric oxide synthase in respiratory diseases
Christian Hesslinger;
Christian Hesslinger
1
1Nycomed GmbH, Byk-Gulden-Strasse 2, 78467 Konstanz, Germany
1To whom correspondence should be addressed (email Christian.Hesslinger@nycomed.com).
Search for other works by this author on:
Andreas Strub;
Andreas Strub
1Nycomed GmbH, Byk-Gulden-Strasse 2, 78467 Konstanz, Germany
Search for other works by this author on:
Rainer Boer;
Rainer Boer
1Nycomed GmbH, Byk-Gulden-Strasse 2, 78467 Konstanz, Germany
Search for other works by this author on:
Wolf-Rüdiger Ulrich;
Wolf-Rüdiger Ulrich
1Nycomed GmbH, Byk-Gulden-Strasse 2, 78467 Konstanz, Germany
Search for other works by this author on:
Martin D. Lehner;
Martin D. Lehner
2
1Nycomed GmbH, Byk-Gulden-Strasse 2, 78467 Konstanz, Germany
Search for other works by this author on:
Clemens Braun
Clemens Braun
1Nycomed GmbH, Byk-Gulden-Strasse 2, 78467 Konstanz, Germany
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
March 05 2009
Online ISSN: 1470-8752
Print ISSN: 0300-5127
© The Authors Journal compilation © 2009 Biochemical Society
2009
Biochem Soc Trans (2009) 37 (4): 886–891.
Article history
Received:
March 05 2009
Citation
Christian Hesslinger, Andreas Strub, Rainer Boer, Wolf-Rüdiger Ulrich, Martin D. Lehner, Clemens Braun; Inhibition of inducible nitric oxide synthase in respiratory diseases. Biochem Soc Trans 1 August 2009; 37 (4): 886–891. doi: https://doi.org/10.1042/BST0370886
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Captcha Validation Error. Please try again.